- Home
- DTCX vs ALXO Comparison
DTCX vs ALXO Comparison
Compare DTCX & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTCX | ALXO |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.5M | 79.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | DTCX | ALXO |
|---|---|---|
| Price | $2.88 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | ★ 347.4K | 173.8K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $0.40 |
| 52 Week High | $4.99 | $2.27 |
Technical Indicators
Market Signals| Indicator | DTCX | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 40.35 |
| Support Level | N/A | $1.37 |
| Resistance Level | N/A | $1.53 |
| Average True Range (ATR) | 0.00 | 0.10 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 3.23 |
Price Performance
Historical ComparisonAbout DTCX Datacentrex Inc. Common Stock
Datacentrex Inc maintains a digital asset treasury composed of assets generated through its mining hashrate, including Dogecoin (DOGE), Litecoin (LTC), and Bitcoin (BTC).
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.